- Home
- Publications
- Publication Search
- Publication Details
Title
Hypoxia as a driver of resistance to immunotherapy
Authors
Keywords
Drug resistance, Immune checkpoint inhibitors, CAR T-cells, Tumor hypoxia
Journal
DRUG RESISTANCE UPDATES
Volume 59, Issue -, Pages 100787
Publisher
Elsevier BV
Online
2021-11-18
DOI
10.1016/j.drup.2021.100787
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance
- (2021) Jing-Quan Wang et al. DRUG RESISTANCE UPDATES
- Insight into next-generation CAR therapeutics: designing CAR T cells to improve clinical outcomes
- (2021) Emiliano Roselli et al. JOURNAL OF CLINICAL INVESTIGATION
- IMbrave150: Updated overall survival (OS) data from a global, randomized, open-label phase III study of atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in patients (pts) with unresectable hepatocellular carcinoma (HCC).
- (2021) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypoxia, endoplasmic reticulum stress and chemoresistance: dangerous liaisons
- (2021) Muhlis Akman et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy
- (2021) Bin Wang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Hypoxia and the phenomenon of immune exclusion
- (2021) Violena Pietrobon et al. Journal of Translational Medicine
- Phase 2 study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 in combination with cabozantinib in patients with advanced clear cell renal cell carcinoma (ccRCC).
- (2021) Toni K. Choueiri et al. JOURNAL OF CLINICAL ONCOLOGY
- The oral HIF-2 α inhibitor MK-6482 in patients with advanced clear cell renal cell carcinoma (RCC): Updated follow-up of a phase I/II study.
- (2021) Todd Michael Bauer et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of avelumab plus axitinib (A + Ax) versus sunitinib (S) by number of IMDC risk factors and tumor sites at baseline in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101.
- (2021) Yoshihiko Tomita et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II study of the oral hypoxia-inducible factor 2α (HIF-2α) inhibitor MK-6482 for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).
- (2021) Othon Iliopoulos et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2021) Toni K. Choueiri et al. NEW ENGLAND JOURNAL OF MEDICINE
- Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
- (2021) Robert Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ex vivo modelling of PD-1/PD-L1 immune checkpoint blockade under acute, chronic, and exhaustion-like conditions of T-cell stimulation
- (2021) Alexander Roberts et al. Scientific Reports
- A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies
- (2021) Aparna Hegde et al. CLINICAL CANCER RESEARCH
- Inhibition of hypoxia-inducible factor-2α in renal cell carcinoma with belzutifan: a phase 1 trial and biomarker analysis
- (2021) Toni K. Choueiri et al. NATURE MEDICINE
- CD73 facilitates EMT progression and promotes lung metastases in triple-negative breast cancer
- (2021) Nataliia Petruk et al. Scientific Reports
- Fundamentals of T Cell Metabolism and Strategies to Enhance Cancer Immunotherapy
- (2021) Guillermo O. Rangel Rivera et al. Frontiers in Immunology
- Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck
- (2021) Dan P Zandberg et al. Journal for ImmunoTherapy of Cancer
- Tumour Hypoxia-Mediated Immunosuppression: Mechanisms and Therapeutic Approaches to Improve Cancer Immunotherapy
- (2021) Zhe Fu et al. Cells
- Novel nanomedicines to overcome cancer multidrug resistance
- (2021) Zhenwei Su et al. DRUG RESISTANCE UPDATES
- Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis
- (2021) Sarah A. Ackroyd et al. GYNECOLOGIC ONCOLOGY
- Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2α (HIF-2α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).
- (2021) Ramaprasad Srinivasan et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab in combination with bevacizumab in patients with unresectable locally advanced or metastatic mucosal melanoma: Interim analysis of an open-label phase II trial.
- (2021) Lu Si et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase 1b/2 umbrella study of investigational immune and targeted combination therapies as first-line therapy for patients with advanced renal cell carcinoma (RCC).
- (2021) Elizabeth R. Plimack et al. JOURNAL OF CLINICAL ONCOLOGY
- Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426.
- (2021) Brian I. Rini et al. JOURNAL OF CLINICAL ONCOLOGY
- The relationship between expression of PD-L1 and HIF-1α in glioma cells under hypoxia
- (2021) Xing-chen Ding et al. Journal of Hematology & Oncology
- Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study
- (2021) Chung-Han Lee et al. LANCET ONCOLOGY
- Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab
- (2021) Vicky Makker et al. ONCOLOGIST
- Medicinal chemistry strategies to discover P-glycoprotein inhibitors: An update
- (2020) Jinyun Dong et al. DRUG RESISTANCE UPDATES
- Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors
- (2020) Matthew H. Taylor et al. JOURNAL OF CLINICAL ONCOLOGY
- Combining microenvironment normalization strategies to improve cancer immunotherapy
- (2020) Fotios Mpekris et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Immune checkpoint signaling and cancer immunotherapy
- (2020) Xing He et al. CELL RESEARCH
- Multifunctional Immunoliposomes Combining Catalase and PD-L1 Antibodies Overcome Tumor Hypoxia and Enhance Immunotherapeutic Effects Against Melanoma
- (2020) Yu Hei et al. International Journal of Nanomedicine
- Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
- (2020) Vicky Makker et al. JOURNAL OF CLINICAL ONCOLOGY
- The impact of tumor hypoxia on the clinical efficacy of anti-PD-1 mAb treatment in recurrent/metastatic HNSCC patients (R/M).
- (2020) Dan Paul Zandberg et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase II randomized trial of first-line pembrolizumab and vorinostat in patients with metastatic NSCLC (mNSCLC).
- (2020) Andreas Nicholas Saltos et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
- (2020) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Tumor Microenvironment: A Milieu Hindering and Obstructing Antitumor Immune Responses
- (2020) Alireza Labani-Motlagh et al. Frontiers in Immunology
- The Lysosomotropic Activity of Hydrophobic Weak Base Drugs is Mediated via Their Intercalation into the Lysosomal Membrane
- (2020) Michal Stark et al. Cells
- Impact of hypoxia on chemoresistance of mesothelioma mediated by the proton-coupled folate transporter, and preclinical activity of new anti-LDH-A compounds
- (2020) Giovanna Li Petri et al. BRITISH JOURNAL OF CANCER
- High expression of AMAP1, an ARF6 effector, is associated with elevated levels of PD-L1 and fibrosis of pancreatic cancer
- (2020) Akio Tsutaho et al. Cell Communication and Signaling
- New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma
- (2020) Michele Dal Bo et al. DRUG RESISTANCE UPDATES
- Hypoxia induced ferritin light chain (FTL) promoted epithelia mesenchymal transition and chemoresistance of glioma
- (2020) Junhui Liu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial
- (2020) Akihito Kawazoe et al. LANCET ONCOLOGY
- Exhausted T cell signature predicts immunotherapy response in ER-positive breast cancer
- (2020) Manuela Terranova-Barberio et al. Nature Communications
- CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape
- (2020) Alba Rodriguez-Garcia et al. Frontiers in Immunology
- Hypoxia Alters Epigenetic and N-Glycosylation Profiles of Ovarian and Breast Cancer Cell Lines in-vitro
- (2020) Gordon Greville et al. Frontiers in Oncology
- 403MO Atezolizumab in combination with bevacizumab for patients with unresectable/metastatic anal cancer
- (2020) V. Morris et al. ANNALS OF ONCOLOGY
- Lactate Exposure Promotes Immunosuppressive Phenotypes in Innate Immune Cells
- (2020) Rapeepat Sangsuwan et al. Cellular and Molecular Bioengineering
- Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance
- (2020) Nir Shahar et al. DRUG RESISTANCE UPDATES
- Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors
- (2020) Andrea B. Apolo et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypoxia-autophagy axis induces VEGFA by peritoneal mesothelial cells to promote gastric cancer peritoneal metastasis through an integrin α5-fibronectin pathway
- (2020) Xiaoxun Wang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Combination of Fruquintinib and Anti–PD-1 for the Treatment of Colorectal Cancer
- (2020) Yuanyuan Wang et al. JOURNAL OF IMMUNOLOGY
- Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial
- (2020) Thomas Powles et al. LANCET ONCOLOGY
- Ectonucleotidase CD73 and CD39 expression in non-small cell lung cancer relates to hypoxia and immunosuppressive pathways
- (2020) Alexandra Giatromanolaki et al. LIFE SCIENCES
- CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?
- (2020) Jessica Wagner et al. MOLECULAR THERAPY
- Targeting the HIF2–VEGF axis in renal cell carcinoma
- (2020) Toni K. Choueiri et al. NATURE MEDICINE
- Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance
- (2020) Nuray Erin et al. DRUG RESISTANCE UPDATES
- Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies
- (2020) Elisabeth Pérez-Ruiz et al. DRUG RESISTANCE UPDATES
- Cholesterol metabolism: At the cross road between cancer cells and immune environment
- (2020) Joanna Kopecka et al. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Regulation of PD-L1 Expression by NF-κB in Cancer
- (2020) Fabrizio Antonangeli et al. Frontiers in Immunology
- Hypoxia Dictates Metabolic Rewiring of Tumors: Implications for Chemoresistance
- (2020) Dimas Carolina Belisario et al. Cells
- CLIC4/Arf6 Pathway
- (2019) Vahitha B. Abdul-Salam et al. CIRCULATION RESEARCH
- Glutaminase 1 expression in colorectal cancer cells is induced by hypoxia and required for tumor growth, invasion, and metastatic colonization
- (2019) Lisha Xiang et al. Cell Death & Disease
- Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
- (2019) Brian I. Rini et al. NEW ENGLAND JOURNAL OF MEDICINE
- Metabolic regulation of CAR T cell function by the hypoxic microenvironment in solid tumors
- (2019) Anna Schurich et al. Immunotherapy
- Glioblastoma cancer stem cell biology: Potential theranostic targets
- (2019) Farzaneh Sharifzad et al. DRUG RESISTANCE UPDATES
- Na+,HCO3− cotransporter NBCn1 accelerates breast carcinogenesis
- (2019) Ebbe Boedtkjer CANCER AND METASTASIS REVIEWS
- Impact of hypoxic tumor microenvironment and tumor cell plasticity on the expression of immune checkpoints
- (2019) Audrey LEQUEUX et al. CANCER LETTERS
- YY1 regulates cancer cell immune resistance by modulating PD-L1 expression
- (2019) Emily Hays et al. DRUG RESISTANCE UPDATES
- A Phase II, single-arm trial of neoadjuvant axitinib plus avelumab in patients with localized renal cell carcinoma who are at high risk of relapse after nephrectomy (NEOAVAX)
- (2019) Axel Bex et al. Future Oncology
- Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial
- (2019) Brian I Rini et al. LANCET
- Mitochondrial metabolism: Inducer or therapeutic target in tumor immune-resistance?
- (2019) Joanna Kopecka et al. SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY
- Hypoxia Selectively Impairs CAR-T Cells In Vitro
- (2019) Robert Berahovich et al. Cancers
- Immune checkpoint inhibitor combinations: Current efforts and important aspects for success
- (2019) Edo Kon et al. DRUG RESISTANCE UPDATES
- The Role of Sodium Hydrogen Exchanger 1 in Dysregulation of Proton Dynamics and Reprogramming of Cancer Metabolism as a Sequela
- (2019) Rosa Cardone et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma
- (2019) Rui Xu et al. JOURNAL OF MEDICINAL CHEMISTRY
- Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial
- (2019) Breelyn A Wilky et al. LANCET ONCOLOGY
- Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non–Small Cell Lung Cancer
- (2019) Jhanelle E. Gray et al. CLINICAL CANCER RESEARCH
- The multi-factorial nature of clinical multidrug resistance in cancer
- (2019) Yehuda G. Assaraf et al. DRUG RESISTANCE UPDATES
- Molecular basis and rationale for combining immune checkpoint inhibitors with chemotherapy in non-small cell lung cancer
- (2019) Alessandro Leonetti et al. DRUG RESISTANCE UPDATES
- STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade
- (2019) Hannah Yang et al. JOURNAL OF CLINICAL INVESTIGATION
- Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy
- (2019) Tongyan Liu et al. Journal of Hematology & Oncology
- The role of collagen in cancer: from bench to bedside
- (2019) Shuaishuai Xu et al. Journal of Translational Medicine
- PD-L1 Distribution and Perspective for Cancer Immunotherapy—Blockade, Knockdown, or Inhibition
- (2019) Yilun Wu et al. Frontiers in Immunology
- LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
- (2019) T Yau et al. ANNALS OF ONCOLOGY
- Tumor angiogenesis: causes, consequences, challenges and opportunities
- (2019) Roberta Lugano et al. CELLULAR AND MOLECULAR LIFE SCIENCES
- Resistance Mechanisms to CAR T-Cell Therapy and Overcoming Strategy in B-Cell Hematologic Malignancies
- (2019) Moo-Kon Song et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Results of a Multicenter Phase II Study of Atezolizumab and Bevacizumab for Patients With Metastatic Renal Cell Carcinoma With Variant Histology and/or Sarcomatoid Features
- (2019) Bradley A. McGregor et al. JOURNAL OF CLINICAL ONCOLOGY
- The role of vascular endothelial growth factor in the hypoxic and immunosuppressive tumor microenvironment: perspectives for therapeutic implications
- (2019) Ryota Tamura et al. MEDICAL ONCOLOGY
- Fate-mapping post-hypoxic tumor cells reveals a ROS-resistant phenotype that promotes metastasis
- (2019) Inês Godet et al. Nature Communications
- Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies
- (2019) Jiali Cheng et al. Frontiers in Oncology
- Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches
- (2019) Karen G. de la Cruz-López et al. Frontiers in Oncology
- Communication between EMT and PD-L1 signaling: New insights into tumor immune evasion
- (2019) Yuanyuan Jiang et al. CANCER LETTERS
- A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer
- (2019) Cristina P. Rodriguez et al. CLINICAL CANCER RESEARCH
- Towards the overcoming of anticancer drug resistance mediated by p53 mutations
- (2019) Xin Cao et al. DRUG RESISTANCE UPDATES
- Phospholipids and cholesterol: Inducers of cancer multidrug resistance and therapeutic targets
- (2019) Joanna Kopecka et al. DRUG RESISTANCE UPDATES
- CTLA4 blockade promotes vessel normalization in breast tumors via the accumulation of eosinophils
- (2019) Xichen Zheng et al. INTERNATIONAL JOURNAL OF CANCER
- Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Hypoxia regulates the mitochondrial activity of hepatocellular carcinoma cells through HIF/HEY1/PINK1 pathway
- (2019) David Kung-Chun Chiu et al. Cell Death & Disease
- Target-Dependent Expression of IL12 by synNotch Receptor-Engineered NK92 Cells Increases the Antitumor Activities of CAR-T Cells
- (2019) Hong Luo et al. Frontiers in Oncology
- Inhibition of the adenosine A2a receptor modulates expression of T cell coinhibitory receptors and improves effector function for enhanced checkpoint blockade and ACT in murine cancer models
- (2018) Robert D. Leone et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer
- (2018) Lydia Meder et al. CANCER RESEARCH
- Tumor-derived lactate induces M2 macrophage polarization via the activation of the ERK/STAT3 signaling pathway in breast cancer
- (2018) Xianmin Mu et al. CELL CYCLE
- How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance
- (2018) Thorsten Stiewe et al. DRUG RESISTANCE UPDATES
- Redundant angiogenic signaling and tumor drug resistance
- (2018) Rajesh N. Gacche et al. DRUG RESISTANCE UPDATES
- Increased vessel perfusion predicts the efficacy of immune checkpoint blockade
- (2018) Xichen Zheng et al. JOURNAL OF CLINICAL INVESTIGATION
- Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia
- (2018) Joseph A. Fraietta et al. NATURE MEDICINE
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma
- (2018) David F. McDermott et al. NATURE MEDICINE
- Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
- (2018) Jae H. Park et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Multifunctional Biomimetic Nanoplatform for Relieving Hypoxia to Enhance Chemotherapy and Inhibit the PD-1/PD-L1 Axis
- (2018) Mei-Zhen Zou et al. Small
- SIRPα–CD47 Immune Checkpoint Blockade in Anticancer Therapy
- (2018) André Veillette et al. TRENDS IN IMMUNOLOGY
- Defining the role of the tumor vasculature in antitumor immunity and immunotherapy
- (2018) Marco B. Schaaf et al. Cell Death & Disease
- Self-Supplied Tumor Oxygenation through Separated Liposomal Delivery of H2O2 and Catalase for Enhanced Radio-Immunotherapy of Cancer
- (2018) Xuejiao Song et al. NANO LETTERS
- Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell
- (2018) Marco Ruella et al. NATURE MEDICINE
- BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1α activation
- (2018) Andrew G. Li et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Activation of LXRɑ/β by cholesterol in malignant ascites promotes chemoresistance in ovarian cancer
- (2018) Soochi Kim et al. BMC CANCER
- Palmitoylation stabilizes PD-L1 to promote breast tumor growth
- (2018) Yi Yang et al. CELL RESEARCH
- Overcoming tumor hypoxia as a barrier to radiotherapy, chemotherapy and immunotherapy in cancer treatment
- (2018) Kaitlin Graham et al. International Journal of Nanomedicine
- Targeted hypoxia reduction restores T cell infiltration and sensitizes prostate cancer to immunotherapy
- (2018) Priyamvada Jayaprakash et al. JOURNAL OF CLINICAL INVESTIGATION
- Lysosomotropic drugs activate TFEB via lysosomal membrane fluidization and consequent inhibition of mTORC1 activity
- (2018) Benny Zhitomirsky et al. Cell Death & Disease
- Hypoxia-induced PD-L1/PD-1 crosstalk impairs T-cell function in sleep apnoea
- (2017) Carolina Cubillos-Zapata et al. EUROPEAN RESPIRATORY JOURNAL
- New horizons in hypoxia signaling pathways
- (2017) Christopher W. Pugh et al. EXPERIMENTAL CELL RESEARCH
- Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial
- (2017) William D Tap et al. LANCET ONCOLOGY
- Identification of CMTM6 and CMTM4 as PD-L1 protein regulators
- (2017) Riccardo Mezzadra et al. NATURE
- CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
- (2017) Marian L. Burr et al. NATURE
- Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
- (2017) Elizabeth Allen et al. Science Translational Medicine
- Loss of HIF-1α in natural killer cells inhibits tumour growth by stimulating non-productive angiogenesis
- (2017) Ewelina Krzywinska et al. Nature Communications
- Structural recognition of tubulysin B derivatives by multidrug resistance efflux transporters in human cancer cells
- (2017) Michal Stark et al. Oncotarget
- Vorinostat suppresses hypoxia signaling by modulating nuclear translocation of hypoxia inducible factor 1 alpha
- (2017) Chao Zhang et al. Oncotarget
- Lysosomal accumulation of anticancer drugs triggers lysosomal exocytosis
- (2017) Benny Zhitomirsky et al. Oncotarget
- An oxygen sensitive self-decision making engineered CAR T-cell
- (2017) Alexandre Juillerat et al. Scientific Reports
- Extracellular Acidic pH Activates the Sterol Regulatory Element-Binding Protein 2 to Promote Tumor Progression
- (2017) Ayano Kondo et al. Cell Reports
- Regulation of Human Macrophage M1–M2 Polarization Balance by Hypoxia and the Triggering Receptor Expressed on Myeloid Cells-1
- (2017) Federica Raggi et al. Frontiers in Immunology
- Hypoxia-inducible factor 3 biology: complexities and emerging themes
- (2016) Cunming Duan AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Biophysics in cancer: The relevance of drug-membrane interaction studies
- (2016) Ana Catarina Alves et al. BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES
- Role of autophagy and lysosomal drug sequestration in acquired resistance to doxorubicin in MCF-7 cells
- (2016) Baoqing Guo et al. BMC CANCER
- Hypoxia regulates ABCG2activity through the activivation of ERK1/2/HIF-1α and contributes to chemoresistance in pancreatic cancer cells
- (2016) Xiaodan He et al. CANCER BIOLOGY & THERAPY
- The Multifaceted Role of Perivascular Macrophages in Tumors
- (2016) Claire E. Lewis et al. CANCER CELL
- Hypoxia-induced modulation of PTEN activity and EMT phenotypes in lung cancers
- (2016) Takashi Kohnoh et al. Cancer Cell International
- Tumor-Intrinsic PD-L1 Signals Regulate Cell Growth, Pathogenesis, and Autophagy in Ovarian Cancer and Melanoma
- (2016) Curtis A. Clark et al. CANCER RESEARCH
- Paracrine Induction of HIF by Glutamate in Breast Cancer: EglN1 Senses Cysteine
- (2016) Kimberly J. Briggs et al. CELL
- LDHA-Associated Lactic Acid Production Blunts Tumor Immunosurveillance by T and NK Cells
- (2016) Almut Brand et al. Cell Metabolism
- Could drugs inhibiting the mevalonate pathway also target cancer stem cells?
- (2016) Wirginia Likus et al. DRUG RESISTANCE UPDATES
- Role of the tumor stroma in resistance to anti-angiogenic therapy
- (2016) Elisabeth J.M. Huijbers et al. DRUG RESISTANCE UPDATES
- The bad seed: Cancer stem cells in tumor development and resistance
- (2016) Elle Koren et al. DRUG RESISTANCE UPDATES
- Lysosomes as mediators of drug resistance in cancer
- (2016) Benny Zhitomirsky et al. DRUG RESISTANCE UPDATES
- Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies
- (2016) Wen Li et al. DRUG RESISTANCE UPDATES
- HIF-2α promotes epithelial-mesenchymal transition through regulating Twist2 binding to the promoter of E-cadherin in pancreatic cancer
- (2016) Jian Yang et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Hyperbaric oxygen as an adjunctive therapy in treatment of malignancies, including brain tumours
- (2016) Katarzyna Stępień et al. MEDICAL ONCOLOGY
- CXCL12 expression and PD-L1 expression serve as prognostic biomarkers in HCC and are induced by hypoxia
- (2016) Alexander Semaan et al. VIRCHOWS ARCHIV
- Arf6 controls retromer traffic and intracellular cholesterol distribution via a phosphoinositide-based mechanism
- (2016) Catherine Marquer et al. Nature Communications
- HIF-1α-PDK1 axis-induced active glycolysis plays an essential role in macrophage migratory capacity
- (2016) Hiroaki Semba et al. Nature Communications
- Zoledronic acid-encapsulating self-assembling nanoparticles and doxorubicin: a combinatorial approach to overcome simultaneously chemoresistance and immunoresistance in breast tumors
- (2016) Joanna Kopecka et al. Oncotarget
- Efficacy of PD-1 Blockade Is Potentiated by Metformin-Induced Reduction of Tumor Hypoxia
- (2016) Nicole E. Scharping et al. Cancer Immunology Research
- Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer
- (2016) Ruea-Yea Huang et al. OncoImmunology
- Cell surface Glut1 levels distinguish human CD4 and CD8 T lymphocyte subsets with distinct effector functions
- (2016) Gaspard Cretenet et al. Scientific Reports
- Regulation of PD-L1: a novel role of pro-survival signalling in cancer
- (2015) J. Chen et al. ANNALS OF ONCOLOGY
- Hypoxia-induced chemoresistance in cancer cells: The role of not only HIF-1
- (2015) Helena Doktorova et al. BIOMEDICAL PAPERS-OLOMOUC
- Hypoxia enhances migration and invasion in glioblastoma by promoting a mesenchymal shift mediated by the HIF1α–ZEB1 axis
- (2015) Justin V. Joseph et al. CANCER LETTERS
- Control of PD-L1 Expression by Oncogenic Activation of the AKT–mTOR Pathway in Non–Small Cell Lung Cancer
- (2015) Kristin J. Lastwika et al. CANCER RESEARCH
- Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression
- (2015) Chih-Hao Chang et al. CELL
- Microenvironment acidity as a major determinant of tumor chemoresistance: Proton pump inhibitors (PPIs) as a novel therapeutic approach
- (2015) Sophie Taylor et al. DRUG RESISTANCE UPDATES
- The modulation of ABC transporter-mediated multidrug resistance in cancer: A review of the past decade
- (2015) Rishil J. Kathawala et al. DRUG RESISTANCE UPDATES
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Associations among pretreatment tumor necrosis and the expression of HIF-1α and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereof
- (2015) Tseng-Cheng Chen et al. ORAL ONCOLOGY
- HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
- (2015) Huimin Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
- (2015) Haiquan Lu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
- (2015) Nikolaos Patsoukis et al. Nature Communications
- Self-assembling nanoparticles encapsulating zoledronic acid revert multidrug resistance in cancer cells
- (2015) Joanna Kopecka et al. Oncotarget
- Simvastatin and downstream inhibitors circumvent constitutive and stromal cell-induced resistance to doxorubicin in IGHV unmutated CLL cells
- (2015) Micol Rigoni et al. Oncotarget
- EML4-ALK enhances programmed cell death-ligand 1 expression in pulmonary adenocarcinoma via hypoxia-inducible factor (HIF)-1α and STAT3
- (2015) Jaemoon Koh et al. OncoImmunology
- Tumor hypoxia drives immune suppression and immunotherapy resistance
- (2015) Midan Ai et al. Journal for ImmunoTherapy of Cancer
- Zoledronic acid overcomes chemoresistance and immunosuppression of malignant mesothelioma
- (2015) Iris Chiara Salaroglio et al. Oncotarget
- Lysosomal sequestration of hydrophobic weak base chemotherapeutics triggers lysosomal biogenesis and lysosome-dependent cancer multidrug resistance
- (2015) Benny Zhitomirsky et al. Oncotarget
- Metabolic orchestration between cancer cells and tumor microenvironment as a co-evolutionary source of chemoresistance in ovarian cancer: A therapeutic implication
- (2014) Dong Hoon Suh et al. BIOCHEMICAL PHARMACOLOGY
- Defining normoxia, physoxia and hypoxia in tumours—implications for treatment response
- (2014) S R McKeown BRITISH JOURNAL OF RADIOLOGY
- The SIRT1/HIF2 Axis Drives Reductive Glutamine Metabolism under Chronic Acidosis and Alters Tumor Response to Therapy
- (2014) C. Corbet et al. CANCER RESEARCH
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
- (2014) Muhammad Zaeem Noman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
- (2014) Gregory T Motz et al. NATURE MEDICINE
- The Histone Deacetylase Inhibitor, Vorinostat, Represses Hypoxia Inducible Factor 1 Alpha Expression through Translational Inhibition
- (2014) Darren M. Hutt et al. PLoS One
- Direct regulation of GAS6/AXL signaling by HIF promotes renal metastasis through SRC and MET
- (2014) Erinn B. Rankin et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Severe hypoxia induces complete antifolate resistance in carcinoma cells due to cell cycle arrest
- (2014) S Raz et al. Cell Death & Disease
- Hostile, Hypoxia-A2-Adenosinergic Tumor Biology as the Next Barrier to Overcome for Tumor Immunologists
- (2014) M. V. Sitkovsky et al. Cancer Immunology Research
- Carbonic anhydrase IX, a hypoxia-induced catalytic component of the pH regulating machinery in tumors
- (2014) Olga Sedlakova Frontiers in Physiology
- Hypoxia downregulates the expression of activating receptors involved in NK-cell-mediated target cell killing without affecting ADCC
- (2013) Mirna Balsamo et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- HIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
- (2013) Gregg L. Semenza JOURNAL OF CLINICAL INVESTIGATION
- Hypoxia Reduces the Efficiency of Elisidepsin by Inhibiting Hydroxylation and Altering the Structure of Lipid Rafts
- (2013) Anna Király et al. Marine Drugs
- Omega 3 fatty acids chemosensitize multidrug resistant colon cancer cells by down-regulating cholesterol synthesis and altering detergent resistant membranes composition
- (2013) Giada Gelsomino et al. Molecular Cancer
- Hypoxia-inducible factors enhance the effector responses of CD8+ T cells to persistent antigen
- (2013) Andrew L Doedens et al. NATURE IMMUNOLOGY
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
- (2013) Stephan A. Grupp et al. NEW ENGLAND JOURNAL OF MEDICINE
- Chemokine C-C motif receptor 5 and C-C motif ligand 5 promote cancer cell migration under hypoxia
- (2012) Sensen Lin et al. CANCER SCIENCE
- The Activation of MAPK in Melanoma Cells Resistant to BRAF Inhibition Promotes PD-L1 Expression That Is Reversible by MEK and PI3K Inhibition
- (2012) X. Jiang et al. CLINICAL CANCER RESEARCH
- Combining angiogenesis inhibition and radiotherapy: A double-edged sword
- (2012) Esther A. Kleibeuker et al. DRUG RESISTANCE UPDATES
- Contribution of PD-L1 to oncogenesis of lymphoma and its RNAi-based targeting therapy
- (2012) Yi Li et al. LEUKEMIA & LYMPHOMA
- HIF2α Acts as an mTORC1 Activator through the Amino Acid Carrier SLC7A5
- (2012) Ainara Elorza et al. MOLECULAR CELL
- The VHL/HIF axis in clear cell renal carcinoma
- (2012) Chuan Shen et al. SEMINARS IN CANCER BIOLOGY
- Control of TH17/Treg Balance by Hypoxia-Inducible Factor 1
- (2011) Eric V. Dang et al. CELL
- Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies
- (2011) G. J. Weiss et al. CLINICAL CANCER RESEARCH
- Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
- (2011) David L. Porter et al. NEW ENGLAND JOURNAL OF MEDICINE
- Interferon- and tumor necrosis factor- induce an immunoinhibitory molecule, B7-H1, via nuclear factor- B activation in blasts in myelodysplastic syndromes
- (2010) A. Kondo et al. BLOOD
- Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19
- (2010) J. N. Kochenderfer et al. BLOOD
- Hypoxia-inducible factor 2α regulates macrophage function in mouse models of acute and tumor inflammation
- (2010) Hongxia Z. Imtiyaz et al. JOURNAL OF CLINICAL INVESTIGATION
- Hypoxia-Inducible Factor 1α Determines Gastric Cancer Chemosensitivity via Modulation of p53 and NF-κB
- (2010) Nadine Rohwer et al. PLoS One
- Tumor Angiogenesis: Insights and Innovations
- (2010) Fernando Nussenbaum et al. Journal of Oncology
- Hypoxia prevents etoposide-induced DNA damage in cancer cells through a mechanism involving hypoxia-inducible factor 1
- (2009) R. Sullivan et al. MOLECULAR CANCER THERAPEUTICS
- Central role of Sp1-regulated CD39 in hypoxia/ischemia protection
- (2008) H. K. Eltzschig et al. BLOOD
- HIF1α Induces the Recruitment of Bone Marrow-Derived Vascular Modulatory Cells to Regulate Tumor Angiogenesis and Invasion
- (2008) Rose Du et al. CANCER CELL
- Effects of lentivirus-mediated HIF-1α knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells
- (2008) J Hao et al. CANCER GENE THERAPY
- Impaired DNA double-strand break repair contributes to chemoresistance in HIF-1 -deficient mouse embryonic fibroblasts
- (2008) R. Wirthner et al. CARCINOGENESIS
- Hypoxia-mediated up-regulation of MGr1-Ag/37LRP in gastric cancers occurs via hypoxia-inducible-factor 1-dependent mechanism and contributes to drug resistance
- (2008) Lili Liu et al. INTERNATIONAL JOURNAL OF CANCER
- Oxygen Sensing by Metazoans: The Central Role of the HIF Hydroxylase Pathway
- (2008) William G. Kaelin et al. MOLECULAR CELL
- PI(3) kinase is associated with a mechanism of immunoresistance in breast and prostate cancer
- (2008) C A Crane et al. ONCOGENE
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started